Adhesive patch biotech Zosano Pharma sets terms for $70 million IPO

Comment

Shutterstock photo

Zosano Pharma, a biotech developing a transdermal delivery system to treat osteoporosis, announced terms for its IPO on Wednesday. The Fremont, CA-based company plans to raise $70 million by offering 6.4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $139 million.

Zosano Pharma, which was spun out of Johnson & Johnson ( JNJ ) in 2006 and booked $3 million in license fee revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol ZSAN. Wedbush PacGrow, Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. No pricing date was disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs
More Headlines for: JNJ , ZSAN


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com